Drug Profile
Bafetinib
Alternative Names: BCR-ABL/Lyn Kinase Inhibitors; CNS-9; INNO-406; NS-187Latest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator Nippon Shinyaku
- Developer LadRx Corporation
- Class Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Bone resorption; Brain cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 07 May 2014 Bafetinib is available for licensing as of 07 May 2014. http://www.cytrx.com
- 18 Mar 2013 CytRx completes a phase I trial in Brain cancer in USA (NCT01234740)